Results 31 to 40 of about 7,154 (184)
Brazilian Journal of Infectious Diseases, 2023 Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García +3 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan +11 more
doaj +1 more source
Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment. [PDF]
, 2023 The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization.
Abdelnabi, Rana +8 more
core +1 more source
Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
, 2023 Nirmatrelvir/ritonavir (Paxlovid) is indicated in patients who are at high risk of progressing to severe COVID-19. Many of these patients are concomitantly prescribed various medications for other indications. Ritonavir has no activity against SARS-CoV-2,
Magdalena Niedzielko +2 more
core +1 more source
Efforts to Develop a Cost-Effective and Scalable Synthetic Process for Nirmatrelvir
, 2022 Nirmatrelvir, the novel antiviral component of Pfizer’s orally available combination therapy Paxlovid, used to treat COVID-19, presents a significant synthetic challenge.
Sarah L., Aleshire +9 more
core +1 more source
Nirmatrelvir-ritonavir et simvastatine
, 2023 International audienceNirmatrelvir-ritonavir et simvastatine L'association nirmatrelvir-ritonavir est indiquée dans le traitement de la Covid-19 chez les patients adultes qui présentent un risque accru d'évolution vers une forme sévère.
Legeay, Samuel, Faure, Sébastien
core +1 more source
Nirmatrelvir Plus Ritonavir: First Approval
, 2022 DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Yvette Lamb (6930427)
core +1 more source
Viruses, 2023 Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this ...
Anna Gidari +9 more
doaj +1 more source
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
Frontiers in Pharmacology, 2023 Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety.Objectives ...
Jiayue Lu +17 more
doaj +1 more source
, 2022 The use of antiviral drugs can promote the appearance of mutations in the target protein that increase the resistance of the virus to the treatment. This is also the case of nirmatrelvir, a covalent inhibitor of the 3CL protease of SARS-CoV-2.
Iñaki, Tuñón +4 more
core +1 more source